ZEO ScientifiX

ZEO ScientifiX Net Margin

The Net Profit Margin of ZEO ScientifiX (ZEOX) as of Nov 1, 2026 is -106.19 %. In the previous year, Net Profit Margin was -101.84 % — a change of 4.28% (lower).

Net Margin

-106.19 %

YoY

4.28%

Last updated:

Net Profit Margin of ZEO ScientifiX is 2025 -106.19 % . Net Profit Margin of ZEO ScientifiX was 2024 -101.84 % . It decreases by 4.28% lower compared to the previous year.

For ZEO ScientifiX, the net margin of -106.2% is up versus -227.9% a few years ago.

The ZEO ScientifiX Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2017
-1,574.33 USD
Jan 1, 2018
-358.96 USD
Jan 1, 2020
-411.78 USD
Jan 1, 2021
-227.90 USD
Jan 1, 2022
-137.06 USD
Jan 1, 2023
-153.29 USD
Jan 1, 2024
-101.84 USD
Jan 1, 2025
-106.19 USD
The ZEO ScientifiX Net Margin history
YEARNet MarginYoY
-106.19 %+4.28%
-101.84 %-33.56%
-153.29 %+11.84%
-137.06 %-39.86%
-227.90 %-44.65%
-411.78 %+14.71%
-358.96 %-77.20%
-1,574.33 %+132.28%
-677.77 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ZEO ScientifiX Stock analysis

What does ZEO ScientifiX do? Organicell Regenerative Medicine Inc generates revenue through its clinical-stage biopharmaceutical products, primarily focusing on regenerative medicine solutions. The company's leading product, Zofin (Organicell Flow), is an acellular biologic therapeutic derived from perinatal sources, containing over 300 growth factors, cytokines, chemokines, and 102 unique microRNAs. This product is administered through doctors and clinics in the healthcare industry, targeting degenerative diseases. The company has secured FDA approvals including IND and eIND, along with IRB authorizations, enabling its therapeutic applications. The company operates within the biotechnology sector, developing biological therapeutics for degenerative conditions. Zofin (Organicell Flow) serves as the core product, leveraging natural microRNAs and exosomes from perinatal tissues without additional substances. Healthcare providers and clinics are the primary buyers of this therapeutic, utilizing it for patient treatments under FDA-approved protocols. The product's unique composition supports its application in regenerative medicine, differentiating it in the market. Organicell Regenerative Medicine Inc's business model centers on the development and commercialization of Zofin (Organicell Flow), which is used in clinical settings for degenerative disease treatment. The company's focus on FDA-approved pathways through IND and eIND approvals ensures regulatory compliance for its product distribution. Healthcare professionals and clinics are the key segments purchasing the product, driven by its therapeutic benefits and natural composition derived from perinatal sources. ZEO ScientifiX is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ZEO ScientifiX stock

Net Profit Margin of ZEO ScientifiX is -106.19 % in 2025.

Net Profit Margin of ZEO ScientifiX changed from -101.84 % to -106.19 %, representing a 4.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin ZEO ScientifiX since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's ZEO ScientifiX with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — ZEO ScientifiX

All Key Metrics — ZEO ScientifiX